Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPKO Health, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Minerva Neurosciences, Inc.

Axsome Therapeutics develops innovative treatments for central nervous system (CNS) conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. The company is focused on bringing new therapies to patients.

Metric
Company Name	Axsome Therapeutics, Inc.	OPKO Health, Inc.	Gilead Sciences, Inc.	Minerva Neurosciences, Inc.
Symbol	AXSM	OPK	GILD	NERV
MSH ID	COM:AXSOME	COM:OPKO	COM:GILEAD	COM:MINERVANEUROSCIENCES
Market	STOCKS	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Medical - Diagnostics & Research	Drug Manufacturers - General	Biotechnology
Country	US	US	US	US
Stage	Post-IPO Equity
Employee Count	569	3.93K	18K	9
Website	axsome.com	opko.com	gilead.com	minervaneurosciences.com
LinkedIn			gilead-sciences
Founders

Metric
Market Cap	3.92B	920.03M	85.65B	23.43M
Enterprise Value
Monthly Web Traffic	7.82K
Web Traffic Growth	-0.74
Valuation
Raised Capital	225M

Metric
Revenue	270.60M	863.50M	27.12B
Revenue (LTM)
Revenue (NTM)
Gross Profit	237.70M	232.09M	27.12B
EBITDA	-176.07M	-52.76M	7.61B
Operating Income	-182.91M	-158.06M	7.61B
Net Income	-239.24M	-188.86M	5.67B
EPS	-5.27	-0.25	4.54
Diluted EPS	-5.27	-0.25	4.50
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.90	0.34	0.78
Operating Profit Margin	-0.86	-0.18	0.36
EBITDA Margin	-0.65	-0.06	0.28
Net Profit Margin	-0.88	-0.22	0.21
Return on Equity	-1.12	-0.13	0.26
Return on Assets	-0.41	-0.09	0.09
Return on Capital Employed	-0.52	-0.09	0.24

COM:AXSOME

Axsome Therapeutics

Last Close

98.19

22/11 21:00

Market Cap

3.92B

Beta: -

Volume Today

425.39K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-20.81	-3.55	16.30
P/B Ratio	16.01	0.51	4.31
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	16.65	1.64	3.91
EV Multiple	-11.57	-3.58	23.26

Metric
Days Sales Outstanding	128.09	49.44	63.83
Days Payables Outstanding	506.28	45.36	36.85
Days Inventory Outstanding	229.29	42.30	205.86
Operating Cycle	383.54	97.34	268.59
Cash Conversion Cycle	-229.81	52.47	262.69
Asset Turnover	0.53	0.43	0.52

Metric
Operating Cash Flow	-145.08M	-28.20M	8.01B
Free Cash Flow	-145.66M	-44.47M	7.42B
Cash Flow to Debt	-0.81	-0.10	0.34
Operating Cash Flow/Sales	-0.54	-0.03	0.31
Free Cash Flow Yield	-0.03	-0.05	0.08

Metric
Cash & Equivalents	386.19M	95.88M	6.08B
Accounts Receivable	-57.12M	3.41M	157M
Inventory	15.13M	65.70M	3.37B
Goodwill	12.04M	598.26M	8.31B
Debt to Capitalization	0.65	0.26	0.60
Debt to Assets	0.31	0.12	0.42
Current Ratio	4.46	1.78	1.34
Quick Ratio	3.46	1.62	1.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.24	0.01	0.02
R&D to Revenue	0.37	0.10	0.21
SG&A to Revenue	0.44